Triple therapy with folfox-based hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, and PD-1 inhibitors significantly prolonged overall survival (24.6 vs 11.9 months) and progression-free survival (10.0 vs 7.7 months) compared to dual therapy. The triple-therapy group also had higher response rates and more patients converted to non-high-risk status, showcasing its potential as a first-line treatment for high-risk advanced hepatocellular carcinoma.
• Why it matters: High-risk advanced hepatocellular carcinoma presents low survival rates and options.
Journal Article by Zuo M, Zheng G (…) Fan W et 4 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.